Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

Here’s where GLP-1 drugs could shift the equation. “If GLP-1 medications can effectively reduce the incidence and severity of ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

GLP-1 medications like Ozempic are reshaping the way people snack, with fewer ultra-processed foods and a shift toward nutrient-packed bites. See what’s in and what’s out.